Literature DB >> 9927209

Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone.

T Biswas1, C V Ramana, G Srinivasan, I Boldogh, T K Hazra, Z Chen, K Tano, E B Thompson, S Mitra.   

Abstract

O6-methylguanine-DNA methyltransferase (MGMT), a ubiquitous DNA repair protein, removes the mutagenic DNA adduct O6-alkylguanine, which is synthesized both endogenously and after exposure to alkylnitrosamines and alkylating antitumor drugs such as 2-chloroethyl-N-nitrosourea (CNU). The MGMT gene is highly regulated in mammalian cells and its overexpression, observed in many types of tumor cells, is often associated with cellular resistance to CNU. Dexamethasone, a synthetic glucocorticoid hormone, was found to increase MGMT expression in HeLa S3 cells, concomitant with their increased resistance to CNU. Two putative glucocorticoid responsive elements (GREs) were identified in the human MGMT (hMGMT) promoter. Transient expression of the luciferase reporter gene driven by an hMGMT promoter fragment containing these GREs was activated by dexamethasone. DNase I footprinting assays demonstrated the binding of glucocorticoid receptor to these sequences. In vitro transcription experiment showed that these DNA sequences are functional in glucocorticoid receptor signal-mediated activation of transcription. These results suggest glucocorticoid-mediated induction of the MGMT gene contributes to high level expression of MGMT.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9927209     DOI: 10.1038/sj.onc.1202320

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

Review 1.  MGMT: a personal perspective.

Authors:  Sankar Mitra
Journal:  DNA Repair (Amst)       Date:  2007-05-07

2.  p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor.

Authors:  Dora Bocangel; Shiladitya Sengupta; Sankar Mitra; Kishor K Bhakat
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

3.  MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.

Authors:  Michael E Fealey; Bernd W Scheithauer; Eva Horvath; Dana Erickson; Kalman Kovacs; Roger McLendon; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

4.  Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

Authors:  Gaspar J Kitange; Brett L Carlson; Mark A Schroeder; Patrick T Grogan; Jeff D Lamont; Paul A Decker; Wenting Wu; C David James; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2008-10-24       Impact factor: 12.300

5.  Bortezomib downregulates MGMT expression in T98G glioblastoma cells.

Authors:  Panagiotis J Vlachostergios; Eleana Hatzidaki; Nikolaos E Stathakis; George K Koukoulis; Christos N Papandreou
Journal:  Cell Mol Neurobiol       Date:  2013-01-20       Impact factor: 5.046

6.  Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.

Authors:  Jonathon F Parkinson; Helen R Wheeler; Adele Clarkson; Catriona A McKenzie; Michael T Biggs; Nicholas S Little; Raymond J Cook; Marinella Messina; Bruce G Robinson; Kerrie L McDonald
Journal:  J Neurooncol       Date:  2007-11-15       Impact factor: 4.130

7.  Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.

Authors:  Sibille Everhard; Jörg Tost; Hafida El Abdalaoui; Emmanuelle Crinière; Florence Busato; Yannick Marie; Ivo G Gut; Marc Sanson; Karima Mokhtari; Florence Laigle-Donadey; Khê Hoang-Xuan; Jean-Yves Delattre; Joëlle Thillet
Journal:  Neuro Oncol       Date:  2009-02-17       Impact factor: 12.300

8.  Influence of promoter/enhancer region haplotypes on MGMT transcriptional regulation: a potential biomarker for human sensitivity to alkylating agents.

Authors:  Meixiang Xu; Ilona Nekhayeva; Courtney E Cross; Catherine M Rondelli; Jeffrey K Wickliffe; Sherif Z Abdel-Rahman
Journal:  Carcinogenesis       Date:  2013-10-25       Impact factor: 4.944

9.  Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.

Authors:  Panagiotis J Vlachostergios; Eleana Hatzidaki; Christina D Befani; Panagiotis Liakos; Christos N Papandreou
Journal:  Invest New Drugs       Date:  2013-05-05       Impact factor: 3.850

Review 10.  The eicosanoid cascade: possible role in gliomas and meningiomas.

Authors:  N Nathoo; G H Barnett; M Golubic
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.